Good MorningThe equities market ended a strong week on an up note despite growing concerns about the COVID-19 pandemic. The number of new cases continues to set new records even as the broad market S&P 500 tries to set a new all-time closing high. The risk for markets is another shutdown. Although, President-Elect Joe Biden’s advisors backed off the suggestion to close the economy for 6 weeks the threat remains.
Next week could be challenging for the market. It is the mid-month data dump and includes eight major economic reports. Among them are Retail Sales, Business Inventories, The Index of Leading Indicators, and a host of housing data. Strong or stronger than expected figures could send the equity market to new all-time highs despite the threat of COVID and there is every reason to think they will be.
Featured: Sell these "safe" blue chips immediately (Ad) 
|
Consumer Discretionary | |
When we consider which stocks have benefitted from market trends caused by the pandemic, usually the first ones that come to mind are cloud-based software companies, e-commerce companies, and any of the “stay-at-home” stocks. On the other hand, the brick-and-mortar retail industry has ... Read the Full Story |
|
From Our Partners | | Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief.
It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live. | | Watch the full story and see the verified track record for yourself |
|
Markets | |
There are several characteristics in a high-quality growth stock that investors should always look for before adding shares to their portfolio. These include things such as strong sales growth, justifiable valuations, and a large target market that is poised to grow for many years to come. One com... Read the Full Story |
|
Consumer Discretionary | |
It's been a tough year for the restaurant industry. Most companies have struggled to put food on the table amid pandemic-led shutdowns and restrictions. There have however been a handful of standout performers that have managed to not just survive but produce some impressive performances despite t... Read the Full Story |
|
From Our Partners | | Moderna's stock doubled in a single day after its cancer vaccine hit key Phase 3 goals, and Merck jumped too. But according to a former Steve Cohen fund manager, the next big opportunity is not Moderna or Merck.
It is a different kind of company tied to a technology already backed by Elon Musk, Sam Altman, Jeff Bezos, and Peter Thiel. Nvidia's Jensen Huang says it will have a dramatic impact on daily life, while Anthropic's CEO believes it could unlock a century of medical progress in just ten years.
Nature Magazine estimates its potential value at $367 trillion globally, and it is already rolling out across the United States. | | Click here to learn about this new era of medical technology |
|
Consumer Discretionary | | A Buying Op In Advanced Auto Parts
It’s been a full quarter since I last reviewed Advanced Auto Parts (NYSE:AAP) and the situation is only more attractive. At the time, I saw the stock on the verge of a breakout and urged investors to wait for a pullback before buying. While the fundamental ... Read the Full Story |
|
Markets | |
There's a school of thought that says job cuts are good for a company's share price because it demonstrates that the company is willing to make the “tough calls” to improve the bottom line. If that's the case, then AT&T (NYSE:T) should be in line for some big gains of its own as th... Read the Full Story |
|
From Our Partners | | Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required.
Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away. | | Discover the gold income fund before the next payout date |
|
Consumer Staples | | Food and beverage maker Campbell Soup Company (NYSE: CPB) shares have been in decline since peaking out at height of the pandemic as the food stockpiling phenomenon surged demand. Shares appear to be setting up for a breakdown underperforming the benchmark S&P 500 index (NYSEARCA: SPY). The adve... Read the Full Story |
|
Consumer Staples | | If It’s A Rotation They Want, Here’s Where The Value Is
The new buzzword on Wall Street is rotation, rotation, rotation. The market (at least in the minds of the mainstream media) is rotating out of growth and big-tech into value. Oddly enough, this is something I’ve been saying f... Read the Full Story |
|
Markets | | A Great Company But Rockwell Automation Is No Value
The stock market has entered a great rotation from growth to value and in that light, Rockwell Automation (NYSE:ROK) is a sell. Trading between 25X and 30X forward earnings it’s highly valued relative to the broad market making it a target f... Read the Full Story |
|
Markets | |
It seems like things are moving faster than ever in financial markets. After equity markets made a huge move up last week, we received even more bullish news that sent stocks soaring to reach new all-time highs during Monday’s trading session. Pfizer (NYSE:PFE) announced that early data from... Read the Full Story |
|
Consumer Discretionary | | Workhorse Group Is About To Melt-Up
The Biden victory is a positive for the EV industry. His renewables-friendly platform will help not only the Workhorse Group but the entire EV market. Within that sphere, however, Workhorse Group is emerging as a leader not only in EV but in a very lucrative nich... Read the Full Story |
|
The Early Bird Stock Of The Day Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. | | View Today's Stock Pick |
|
